PSMA-targeted radioligand therapies for prostate cancer.
| Date | Round | Amount |
|---|---|---|
| Nov 2024 | Series A Blue Earth Therapeutics raised a USD 76.5M Series A led by Soleus Capital and Sands Capital for its prostate-cancer radioligand therapies. | $76.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.